Tc 99-Sesta Mibi Uptake In Nonsecretory Multiple Myeloma(557 views) Catalano L, Andretta C, Pace L, Del Vecchio S, Salvatore B, De Rosa G, Buonanno MT, Paone G, Rotoli B
Keywords: Conventional Imaging (ci), Monoclonal Component (mc), Nonsecretory Multiple Myeloma, Tc99m-Sestamibi Scintigraphy, Methoxy Isobutyl Isonitrile Technetium Tc 99m, Adult, Article, Bone Marrow, Cancer Diagnosis, Cancer Localization, Cancer Staging, Clinical Article, Computer Assisted Tomography, Female, Follow Up, Human, Nuclear Magnetic Resonance, Outcomes Research, Priority Journal, Radiodiagnosis, Remission, Sensitivity And Specificity, Treatment Duration, X Ray, Middle Aged, Monitoring, Physiologic, Radionuclide Imaging, Radiopharmaceuticals, Technetium Tc 99m Sestamibi,
Affiliations: *** IBB - CNR ***
Division of Hematology, Universit Federico II, Napoli, Italy
Division of Nuclear Medicine, Universit Federico II, Napoli, Italy
Divisions of Hematology, Universit Federico II, Napoli, Italy
References: Not available.
Tc 99-Sesta Mibi Uptake In Nonsecretory Multiple Myeloma
Staging and monitoring of multiple myeloma (MM) is mainly based on monoclonal component quantification; the absence of such a parameter renders difficult follow up of patients with nonsecretory MM (nsMM). In this study our aims were to determine the specificity and sensitivity of Tc99m-sestaMIBI scintigraphy at diagnosis and during follow up of nsMM patients. Nine nsMM patients were prospectively studied at diagnosis and during treatment for a mean time of 33 months (range: 12-65 +). Tc99m-sestaMIBI (MIBI) scintigraphy was compared to conventional imaging (CI: X ray with CAT or NMR details) at diagnosis and during follow up. At diagnosis, CI and MIBI were concordant in three patients; CI showed more focal lesions than MIBI in four patients, while MIBI revealed more focal lesions than CI in two patients. During the follow up, MIBI uptake was normal in the four patients who achieved remission. Five patients did not achieve remission: CI and MIBI were concordant in three, while MIBI was falsely negative in two patients. In conclusion, Tc99m-sestaMIBI scintigraphy has high sensitivity (no false positive cases) and 78% specificity (2/9 false negative cases) in tracing active nsMM lesions; it should be considered complementary to CI for monitoring this rare disease. 2005 Taylor & Francis Group Ltd
Tc 99-Sesta Mibi Uptake In Nonsecretory Multiple Myeloma
No results.
Tc 99-Sesta Mibi Uptake In Nonsecretory Multiple Myeloma
Hesse B, Tagil K, Cuocolo A, Anagnostopoulos C, Bardies M, Bax J, Bengel F, Busemann Sokole E, Davies G, Dondi M, Edenbrandt L, Franken P, Kjaer A, Knuuti J, Lassmann M, Ljungberg M, Marcassa C, Marie PY, Mckiddie F, O'connor M, Prvuolovich E, Underwood R * 3. 0 T perfusion MR imaging(896 views) Rivista Di Neuroradiologia (ISSN: 1120-9976), 2004; 17(6): 807-812. Impact Factor:0.023 ViewExport to BibTeXExport to EndNote